BLTE (Belite Bio) Institutional Ownership: 22.75% (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLTE Belite Bio Inc BLTE
21 GF Score
Price $159.30
! 3 Warning Signs
View Full Analysis

What is Belite Bio Institutional Ownership?

Belite Bio BLTE -0.89% 21 Institutional Ownership is 22.75% as of Aug. 03, 2026. GuruFocus rates BLTE with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Belite Bio's institutional ownership is 22.75%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Belite Bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Belite Bio's Float Percentage Of Total Shares Outstanding is 51.92%.

Belite Bio Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Belite Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Institutional Ownership Chart

Belite Bio Historical Data

The historical data trend for Belite Bio can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.65 0.67 0.67 1.66 1.63 1.64 1.61 1.63 1.66 1.57
BLTE
21GF Score
Belite Bio Inc BLTE
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Belite Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 22.75% mean?
Belite Bio (BLTE) has a Institutional Ownership of 22.75% as of Aug. 03, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Belite Bio and its competitors.
Is Belite Bio's Institutional Ownership too high?
Belite Bio's current Institutional Ownership is 22.75%. Overall, Belite Bio has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Institutional Ownership compare to CGON and LGND?
Belite Bio's Institutional Ownership of 22.75% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Belite Bio and its competitors. Belite Bio's current Institutional Ownership is 22.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (BLTE) has a current Institutional Ownership of 22.75%. The current Institutional Ownership is 22.75%. Belite Bio's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Belite Bio (BLTE), the current Institutional Ownership is 22.75% as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belite Bio Business Description

Other Exchanges D01:Germany
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
21GF Score

Get the complete analysis for BLTE

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$159.30
Price